500 million injections!

Medical Network, March 8 News On March 4, the official website of CDE showed that Hebei Renhe Yikang Pharmaceutical's dexmedetomidine hydrochloride injection was accepted as imitation 3 types
.
Since this year, dexmedetomidine hydrochloride injection has been submitted by Yunnan Longhai Natural Plant Pharmaceuticals and Chenxin Pharmaceuticals for listing applications under review (in the Center for Drug Evaluation)
.
According to data from Meinenet, the sales of terminal dexmedetomidine injections in China's public medical institutions exceeded 3.
5 billion yuan in 2019
.
Currently, there are 12 manufacturers of dexmedetomidine hydrochloride injection, including Yangzijiang Pharmaceutical Group, Jiangsu Hengrui Pharmaceutical, Hunan Kelun Pharmaceutical, and Chengdu Better Pharmaceutical; dexmedetomidine hydrochloride sodium chloride injection There is only Jiangsu Hengrui Medicine
.
Data show that dexmedetomidine hydrochloride is a relatively selective α2-adrenergic receptor agonist, which is suitable for tracheal intubation and sedation during mechanical ventilation in surgical patients undergoing general anesthesia, and is used during intensive care treatment.
Tube and sedation of patients using a ventilator
.
In recent years, the sales of dexmedetomidine injections in public medical institutions in China.
Source: The competitive landscape of public medical institutions in China.
According to data from Minet.
com, in 2019, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as China) The sales of terminal dexmedetomidine injections in public medical institutions exceeded 3.
5 billion yuan, and the growth rate declined in the first half of 2020
.
Among them, Yangtze River Pharmaceutical Group has the largest market share, exceeding 80%
.
Currently, there are 12 manufacturers of dexmedetomidine hydrochloride injection, including Yangzijiang Pharmaceutical Group, Jiangsu Hengrui Pharmaceutical , Hunan Kelun Pharmaceutical, and Chengdu Better Pharmaceutical ; dexmedetomidine hydrochloride sodium chloride injection There is only Jiangsu Hengrui Medicine
.
Source: MED2.
0 Chinese Drug Evaluation Database Consistency evaluation, dexmedetomidine hydrochloride injection has been given eight companiesThrough evaluation, Yangtze River Pharmaceutical Group and Sinopharm Group Industry have been approved for imitation of 3 categories as evaluation, and Jiangsu Hengrui Pharmaceutical, Hunan Kelun Pharmaceutical, Chengdu Beite Pharmaceutical and other 6 companies have been approved as supplementary applications Evaluation; Dexmedetomidine Hydrochloride and Sodium Chloride Injection Jiangsu Hengrui Medicine has been approved for imitation of Category 3 and is deemed to have been reviewed
.
Source: MED2.
0 Chinese Drug Evaluation Database Up to now, 8 companies including Nanjing Zhengda Tianqing Pharmaceutical, CSPC Yinhu Pharmaceutical, Jiangsu Zhengda Qingjiang Pharmaceutical and other 8 companies have submitted application for listing as generic 3 types of dexmedetomidine hydrochloride injection.
Under review and approval (in the Center for Drug Evaluation); Dexmedetomidine Hydrochloride and Sodium Chloride Injection has Yangzijiang Pharmaceutical Group, Hunan Kelun Pharmaceutical, and Chengdu Beite Pharmaceutical to submit marketing applications for generic 3 types.
Under review and approval Medium (at the Drug Evaluation Center)
.
Source: CDE official website, Minet database